NORDIQC DATA FOR BREAST MARKERS

Antibody selection, protocols and controls

NordiQC Workshop, October 4-6th 2023

Heidi Lykke Kristoffersen
Staff Scientist
NordiQC

NORDIQC EQA DATA FOR IHC BREAST MARKERS

		Purpose	Last run	Pass rate	No of labs
Type I IHC tests	GATA3	Breast vs non-breast	Run 63, 2021	68%	320
	Mammaglobin	Breast vs non-breast	Run 25, 2009	83%	23
	GCDFP15	Breast vs non-breast	Run 36, 2012	86%	131
	CK5	CIS vs invasive	Run 65, 2022	71%	311
	SMH	CIS vs invasive	Run 66, 2022	81%	152
	p63	CIS vs invasive	Run 61, 2021	79%	324
	E-Cadherin	Ductal vs lobular	Run 53, 2018	89%	298
Type II IHC tests	KI67	PI index	Run B22, 2016	93%	409
	ER	Predictive for Tamoxifen	Run B35, 2023	91%	422
	PR	Predictive for Tamoxifen	Run B35, 2023	92%	414
	HER2 IHC	Predictive for Herceptin	Run B35, 2023	90%	403
	HER2 BRISH	Predictive for Herceptin	Run H23, 2023	59%	163
	PD-L1 IC	Predictive for Tecentriq	Run C13, 2023	68%	139
	PD-L1 TPS/CPS	Predictive for Keytruda	Run C13, 2023	92%	243



KEY-POINTS FOR BEST PROTOCOLS

- Clone selection
- RTUs – “Plug and Play” or “Play and Plug”?
- Efficient HIER, preferable in an alkaline buffer
- Use of right detection system

- Use of iCAPS

CLONE PERFORMANCE FOR SELECTED BREAST MARKERS

Marker	Successful clones	Less successful clones
GATA3	mAb L50-823, rmAb SP368	mAb HG3-31
CK5*	mAb XM26, rmAb SP27	mAb D5/16 B4
SMH	mAb SMMS1	-
p63	mAbs 4A4 & DAK-p63	mAb 7JUL
E-Cadherin	mAbs NCH-38, 36 & 36B5	rmAb EP700Y
KI67	mAb MIB-1, rmAb 30.9	-
ER	rmAbs SP1 & EP1, mAb 6F11	-
PR	mAbs 16 & PgR1294, rmAbs 1E2 & Y85	-
HER2 IHC	rmAbs 4B5 & DG44, Dako pAb	mAb CB11
PD-L1 IC	rmAb SP142	*Non-SP142*
PD-L1 TPS/CPS*	mAb 22C3, rmAb SP263	*rmAb SP142*

*see ppt for lung-markers

ICAPS FOR SELECTED BREAST MARKERS

Marker	IHC critical assay performance controls Low expression	Negative tissue controls No expression	
GATA3	Tonsil: T-helper-cells in the T-zones and germinal centers.	Tonsil: B-cells, squamous epithelial cells, endothelial cells.	Link
Mammaglobin	Skin: Epithelial cells of eccrine sweat glands.	Tonsil: All cell types.	Link
GCDFP15	Skin: Epithelial cells of eccrine sweat glands.	Tonsil: All cell types.	Link
CK5	Pancreas: Scattered epithelial cells of intercalated ducts.	Liver. All cell types.	Link
Smooth MHCM	Tonsil: Follicular dendritic cells in germinal centers.	Tonsil: Epithelial cells.	Link
p63	Placenta: Cytotrophoblastic cells.	Appendix: Epithelial- and smooth muscle cells.	Link
E-Cadherin	Liver: Hepatocytes.	Appendix: Stromal cells, smooth muscle cells, endothelial cells.	Link
KI67	Tonsil: B-cells in the light zones of the germinal centers.	Liver: Hepatocytes	Link
ER	Tonsil: Squamous epithelial cells, T-cells in germinal centres.	Tonsil: B-cells in mantle zone and germinal centres.	Link
PR	Cervix: Basal squamous epithelial cells.	Tonsil: All cells types (especially focus on lymphocytes in germinal centres).	Link
PD-L1 IC	Tonsil: T-cells and macrophages in germinal centres.	Tonsil: Normal squamous epithelial cells, lymphocytes.	Link
PD-L1 TPS/CPS	Tonsil: Germinal center macrophages and T-cells.	Tonsil: Stratified normal squamous epithelial cells and vast majority of lymphocytes.	Link



KEY-POINTS FOR BEST PROTOCOLS

Selected breast markers:

Overall pass rate: **85%** (2.078/2.450), ranging from 67% for GATA3 till 92% for PR.

KEY-POINTS FOR BEST PROTOCOLS

Breast markers:

Overall pass rate: **85%**

HIER in High pH: 86%

Ranging from 69% for GATA3 till 95% for HER2

HIER in Low pH: 73%

*Ranging from 50% for ECAD, GATA3 and SMH till 100% for PR**

**15/15 participants used a low pH buffer, on a Leica or Dako platform.*



KEY-POINTS FOR BEST PROTOCOLS



Breast markers:

3-layer detection system: 83%

2-layer detection system: 88%

KEY-POINTS FOR BEST PROTOCOLS



Breast markers:

3-layer detection system: 83%

2-layer detection system: 88%

Type I tests

3-layer detection system: 81%

2-layer detection system: 71%

KEY-POINTS FOR BEST PROTOCOLS



Breast markers:

3-layer detection system: 83%

2-layer detection system: 88%

Type I tests

3-layer detection system: 81%

2-layer detection system: 71%

Type II test

3-layer detection system: 87%

2-layer detection system: 95%

NOW TIME TO LOOK AT SOME SPECIFIC MARKERS

GATA3 – PITFALLS/POINTS OF ATTENTION

Table 1. **Antibodies and assessment marks for GATA3, Run 63**

Concentrated antibodies	n	Vendor	Optimal	Good	Borderline	Poor	Suff.[1]	OR[2]
mAb clone **L50-823**	88 24 4 3 3 2 2 1 1	Cell Marque Biocare BD Pharmingen Zytomed Systems Gennova Bio-SB Immunologic Anacrom DBS	31	40	33	24	56%	25%
rmAb clone **EP368**	5 1	Cell Marque Quartett	4	-	1	1	67%	67%
mAb clone **HG3-31**	2	Santa Cruz	-	-	-	2	-	-
rmAb clone **ZR65**	1	Zeta Corporation	-	-	1	-	-	-
Conc total	137		35	40	35	27	55%	26%
Ready-To-Use antibodies							Suff.[1]	OR.[2]
mAb clone **L50-823 760-4897**[3]	56	Ventana/Roche	36	12	8	-	86%	64%
mAb clone **L50-823 760-4897**[4]	67	Ventana/Roche	41	16	7	3	85%	61%
mAb clone **L50-823 390M-17,18,10**	42	Cell Marque	14	12	13	3	62%	33%
mAb clone **L50-823 PM 405AA**	12	BioCare Medical	5	3	2	2	67%	42%
mAb clone **L50-823 MAD-000632QD**	3 1	Master Diagnostica Vitro SA	1	2	1	-	-	-
mAb clone **L50-823 CGM-0130**	1	Celnovte	-	1	-	-	-	-
mAb clone **GATA3/6664 AMB89**	1	BioGenex	-	-	-	1	-	-
RTU total	183		97	46	31	9	78%	53%
Total	320		132	86	66	36		
Proportion			41%	27%	21%	11%	68%	

1) Proportion of sufficient results (optimal or good). (≥5 asessed protocols).
2) Proportion of Optimal Results (OR).
3) Vendor Recommended Protocol Settings (VRPS) to a specific RTU product applied on the vendor recommended platform(s) (≥5 asessed protocols).
4) Laboratory Modified Protocol Settings (LMPS) to a specific RTU product applied either on the vendor recommended platform(s), non-validated semi/fully automatic systems or used manually (indicated in percentage if ≥5 asessed protocols).

Table 2. **Proportion of optimal results for GATA3 for the most commonly used antibodies as concentrate on the four main IHC systems***

Concentrated antibody	Dako/Agilent Autostainer		Dako/Agilent Omnis		Ventana/Roche BenchMark XT / Ultra		Leica Biosystems Bond III / Max	
	TRS pH 9.0	TRS pH 6.1	TRS pH 9.0	TRS pH 6.1	CC1 pH 8.5	CC2 pH 6.0	BERS2 pH 9.0	BERS1 pH 6.0
mAb clone **L50-823**	1/12** (8%)	0/1	11/36 (31%)	0/1	15/46 (33%)	0/1	4/19 (21%)	-
rmAb clone **EP368**	1/1	-	2/2	-	0/1	-	0/1	-

* Antibody concentration applied as listed above, HIER buffers and detection kits used as provided by the vendors of the respective systems.
** (number of optimal results/number of laboratories using this buffer).

No RTU products for Dako and Leica users.
Use of conc. format of mAb L50-823 - and rmAb clone EP368 on Dako platforms - can obtain optimal results.

Recommended protocol settings:

- HIER in an alkaline buffer

- 40% pass rate for 2-step detection systems (8% optimal)
- 76% pass rate for 3-step detection systems (50% optimal)

SMH - PITFALLS/POINTS OF ATTENTION

Table 3. **Proportion of sufficient and optimal results for SMH for the most commonly used RTU IHC systems**

RTU systems	Recommended protocol settings*		Laboratory modified protocol settings**	
	Sufficient	Optimal	Sufficient	Optimal
Dako AS mAb SMMS-1 **IR/IS066**	73% (8/11)	18% (2/11)	86% (6/7)	57% (4/7)
Leica BOND mAb S131 **PA0493**	100% (7/7)	100% (7/7)	3/3	2/3
VMS Ultra/XT mAb SMMS-1 **760-2704**	87% (13/15)	67% (10/15)	95% (38/40)	60% (24/40)

* Protocol settings recommended by vendor – Retrieval method and duration, Ab incubation times, detection kit, IHC stainer/equipment.
** Significant modifications: retrieval method, retrieval duration and Ab incubation time altered >25%, detection kit – only protocols performed on the specified vendor IHC stainer integrated.

Table 2. **Proportion of optimal results for SMH for the most commonly used antibody as concentrate on the 4 main IHC systems***

Concentrated antibodies	Dako/Agilent Autostainer Link / Classic		Dako/Agilent Omnis		Ventana/Roche BenchMark GX / XT / Ultra		Leica Biosystems Bond III / Max	
	TRS pH 9.0	TRS pH 6.1	TRS pH 9.0	TRS pH 6.1	CC1 pH 8.5	CC2 pH 6.0	ER2 pH 9.0	ER1 pH 6.0
mAb **SMMS-1**	0/1**	-	6/7 (86%)	0/1	8/12 (67%)	-	6/8 (75%)	(1/1)

* Antibody concentration applied as listed above, HIER buffers and detection kits used as provided by the vendors of the respective systems.
** (number of optimal results/number of laboratories using this buffer)

No RTU for Omnis is available. 13 laboratories used the Autostainer RTU on the Omnis; 15% pass rate, none optimal.

Limited data for concentrated formats on Omnis, but possible to achieve an optimal staining.



NordiQC — Nordic Immunohistochemical Quality Control
Institute of Pathology, Aalborg University Hospital, Ladegaardsgade 3, P.O.Box 561, DK-9100 Aalborg, Denmark

Recommended protocol for SMH
Obtained in run 66
12 Jul 2022

Immunostainer
Type: Dako Omnis

Primary antibody
Clone: SMMS-1
Producer: Cell Marque
Product no. / lot no.: 298M-14/15/16 / 0000144768
Diluent: Antibody Diluent
Dilution factor: 1:400
Incubation time / temperature: 30 min. / 32°C

Epitope retrieval, HIER
Device: On Board / On Machine
Buffer: Dako Omnis Target Retrieval Solution, High pH
Heating time at max. temp.: 30 min.
Maximum heating temp.: 97°C

Visualization system
Producer: Dako Omnis
Product / no: EnVision Flex / GV800/GV823
Linker: Mouse LINKER
Incubation time linker: 10 min.
Incubation time polymer: 20 min.
Incubation temperature: 32°C

Chromogen
Producer: Dako Omnis
Product / no: DAB+ Substrate Chromogen System / GV825
Incubation time / temperature: 5 min. / 32°C
Enhancement: None

Disclaimer:
NordiQC makes every attempt to provide accurate and up-to-date information, yet NordiQC does not make any claim or warranty regarding the accuracy of the provided information nor does it represent that the contents of the web site and protocols reflect the most recent developments in immunohistochemistry at any point in time.

P63 - PITFALLS/POINTS OF ATTENTION

Table 3. Proportion of sufficient and optimal results for p63 for the most commonly used RTU IHC systems

RTU systems	Recommended protocol settings*		Laboratory modified protocol settings**	
	Sufficient	Optimal	Sufficient	Optimal
VMS Ultra/XT mAb 4A4 **790-4509**	57% (4/7)	0/7	88% (100/114)	52% (59/114)
Dako AS48 mAb DAK-p63 **IR662**	91% (11/12)	17% (2/12)	57% (4/7)	0/7
Dako Omnis mAb DAK-p63 **GA662**	85% (17/20)	25% (5/20)	100% (13/13)	62% (8/13)
Leica Bond mAb 7JUL **PA0103**	1/4	0/4	0/6	0/6

* Protocol settings recommended by vendor – Retrieval method and duration, Ab incubation times, detection kit, IHC stainer/equipment.
** Significant modifications: retrieval method, retrieval duration and Ab incubation time altered, detection kit – only protocols performed on the specified vendor IHC stainer integrated.

Table 2. **Proportion of optimal results for p63 for the most commonly used antibody as concentrate on the four main IHC systems***

Concentrated antibodies	Dako/Agilent Autostainer		Dako/Agilent Omnis		Ventana/Roche BenchMark GX / XT / Ultra		Leica Bond III / Max	
	TRS pH 9.0	TRS pH 6.1	TRS pH 9.0	TRS pH 6.1	CC1 pH 8.5	CC2 pH 6.0	ER2 pH 9.0	ER1 pH 6.0
mAb clone **4A4**	0/3**	0/1	1/2	-	9/20 (45%)	-	1/7 (14%)	0/1
mAb clone **DAK-p63**	0/3	-	4/9 (44%)	0/1	17/24 (71%)	-	0/9	-
mAb clone **7JUL**	-	-	-	-	0/4	-	0/6	0/1

* Antibody concentration applied as listed above, HIER buffers and detection kits used as provided by the vendors of the respective systems.
** (number of optimal results/number of laboratories using this buffer).

Vendor recommended protocol based on UltraView and 16-20 min. incubation of primary Ab.
Most common and successful modification was prolonging incubation time and use of OptiView or UltraView with amplification.

Vendor recommended protocol based on HIER in TRS Low pH.
Most successful modification was using HIER in TRS High pH.

Less successful performance for 7JUL on the Bond platform.
Limited data for Bond users, but conc. 4A4 might be the best solution.

P63 - PITFALLS/POINTS OF ATTENTION





Courtesy Ole Nielsen, Dept. of Pathology, OUH, Denmark

ECAD - PITFALLS/POINTS OF ATTENTION

Table 1. **Antibodies and assessment marks for ECAD, run 53**

Concentrated antibodies	n	Vendor	Optimal	Good	Borderline	Poor	Suff.[1]	Suff. OPS[2]
mAb clone **NCH-38**	82 1 1	Agilent/Dako Immunologics Thermo S./Neomarkers	57	22	4	1	94%	98%
mAb clone **36**	1 1	BD Biosciences Biogenex	0	1	0	1	-	-
mAb clone **36B5**	13	Leica/Novocastra	2	10	1	0	92%	100%
mAb clone **4A2C7**	4	Life Tech./Invitrogen	2	2	0	0	-	-
mAb clone **BS38**	1	Nordic Biosite	0	1	0	0	-	-
mAb clone **DBM15.49**	1	Diagnostic BioSystems	1	0	0	0	-	-
mAb clone **ECH-6**	2	Zytomed Systems	1	0	1	0	-	-
mAb clone **HECD-1**	9 1	Life Tech./Invitrogen Takara Bio Inc.	4	5	0	1	90%	100%
mAb clone **GM016**	1	Genemed	1	0	0	0	-	-
mAb clone **SPM471**	1	Thermo S./Neomarkers	0	0	1	0	-	-
rmAb **EP700Y**	5	Cell Marque	0	4	1	0	-	-
rmAb **EP6**	1	Zeta Corporation	0	1	0	0	-	-
Ready-To-Use antibodies								
mAb clone **36 790-4497**	68	Roche/Ventana	54	11	3	0	96%	100%
mAb clone **GM016 8229-C010**	2	Sakura Finetek	2	0	0	0	100%	-
mAb clone **NCH-38 GA059**	31	Agilent/Dako	31	0	0	0	100%	100%
mAb clone **NCH-38 GA059**[3]	6	Agilent/Dako	5	1	0	0	-	-
mAb clone **NCH-38 IS/IR059**	27	Agilent/Dako	26	1	0	0	100%	100%
mAb clone **NCH-38 IS/IR059**[3]	6	Agilent/Dako	4	2	0	0	-	-
mAb clone **MX020 MAB-0738**	1	Maixin	0	1	0	0	100%	-
mAb clone **BS38 MAD-000643QD**	1	Master Diagnostica	1	0	0	0	100%	-
mAb clone **HECD-1 MAD-000761QD**	1	Master Diagnostica	1	0	0	0	100%	-
mAb clone **35B5 PA0387**	6	Leica/Novocastra	0	6	0	0	100%	-
rmAb clone **EP700Y 760-4440**	17	Roche/Ventana	0	2	15	0	13%	-
rmAb clone **EP700Y 246R-18**	6	Cell Marque	0	1	5	0	-	-
mAb clone **EP6 API3012**	1	Biocare Medical	0	1	0	0	100%	-
Total	298		192	72	31	3	-	
Proportion			65%	24%	10%	1%	89%	

1) Proportion of sufficient stains (optimal or good).
2) Proportion of sufficient stains with optimal protocol settings only, see below.
3) Ready-to-use product developed for a specific semi/fully automated platform by a given manufacturer but inappropriately applied by laboratories on other non-validated semi/fully automatic systems or used manually.

Table 3. **Proportion of optimal results for ECAD for the most commonly used antibody as concentrate on the 4 main IHC systems***

Concentrated antibodies	Dako Autostainer Link / Classic		Dako Omnis		Ventana BenchMark XT / Ultra		Leica Bond III / Max	
	TRS pH 9.0	TRS pH 6.1	TRS pH 9.0	TRS pH 6.1	CC1 pH 8.5	CC2 pH 6.0	ER2 pH 9.0	ER1 pH 6.0
mAb clone **NCH-38**	8/10** (80%)	-	1/1	-	32/42 (76%)	-	6/6 (100%)	0/2

* Antibody concentration applied as listed above, HIER buffers and detection kits used as provided by the vendors of the respective syatems.
** (number of optimal results/number of laboratories using this buffer)

Concentrated format of mAb NCH-38 works on the main IHC Systems

Table 4. **Proportion of sufficient and optimal results for ECAD for the most commonly used RTU IHC systems**

RTU systems	Recommended protocol settings*		Laboratory modified protocol settings**	
	Sufficient	Optimal	Sufficient	Optimal
Dako AS mAb NCH-38 **IS/IR059**	100% (10/10)	100% (10/10)	100% (13/13)	100% (13/13)
Dako Omnis mAb NCH-38 **GA059**	100% (21/21)	100% (21/21)	(3/3)	(3/3)
VMS Ultra/XT/GX mAb 36 **790-4497**	100% (11/11)	72% (8/11)	95% (54/57)	81% (46/57)

* Protocol settings recommended by vendor – Retrieval method and duration, Ab incubation times, detection kit, IHC stainer/equipment.
** Significant modifications: retrieval method, retrieval duration and Ab incubation time altered >25%, detection kit – only protocols performed on the specified vendor IHC stainer were included.

RTU assays work as “plug-and-play” products.
The majority of RTU assays obtain high pass rates
– except assays based on rmAb EP700Y

ER – PITFALLS / POINTS OF ATTENTION

Table 3. **Comparison of pass rates for vendor recommended and laboratory modified RTU protocols**

RTU systems	Vendor recommended protocol settings*		Laboratory modified protocol settings**	
	Sufficient	Optimal	Sufficient	Optimal
Dako AS48 rmAb EP1 **IR084/IS084**	3/3	1/3	18/21 (86%)	4/21 (19%)
Dako Omnis rmAb EP1 **GA084**	41/42 (98%)	29/42 (69%)	23/23 (100%)	12/23 (52%)
Leica Bond mAb 6F11 **PA009/PA0151**	2/2	0/2	12/19 (63%)	8/19 (42%)
VMS Ultra/XT/GX rmAb SP1 **790-4324/4325**	50/50 (100%)	30/50 (60%)	169/180 (94%)	121/180 (67%)

* Protocol settings recommended by vendor – Retrieval method and duration, Ab incubation times, detection kit, IHC stainer/equipment.
** Modifications included: retrieval method, retrieval duration, retrieval reagents, Ab incubation time, detection kit and use of amplification. Only protocols performed on the specified vendor IHC stainer are included.

Even with these successful results, changing RTU assays requires internal validation.

For Dako and Ventana products, the most common modification was using a 3-step detection system.

For Leica, modification in HIER – changing from low till high pH buffer was made the majority of participants.



Fig. 6a
Optimal ER staining of the breast carcinoma no. 5 expected to be negative using same protocol as in Figs. 1a – 5a. No nuclear staining reaction is seen and a high signal-to-noise ratio is observed.



Fig. 6b
Insufficient ER staining of the breast carcinoma no 5 with no ER expression. A weak but distinct nuclear staining reaction is seen in >10% of the neoplastic cells.
The insufficient result was only seen for the mAb clone 6F11 and likely was caused by performing HIER in an alkaline buffer in combination with other protocol settings inducing a too high level of technical/analytical IHC sensitivity compromising the diagnostic specificity.

PR – PITFALLS / POINTS OF ATTENTION

Table 1. **Antibodies and assessment marks for PR, run B31**

Concentrated antibodies	n	Vendor	Optimal	Good	Borderline	Poor	Suff.[1]	OR[2]
mAb clone **16**	33 1	Leica Biosystems Monosan	20	12	-	2	94%	59%
mAb clone cocktail **16 + SAN27**	5	Leica Biosystems	2	2	1	-	80%	40%
rmAb clone **BP6081**	1	Biolynx	-	1	-	-	-	-
mAb clone **PgR 636**	13 1	Dako/Agilent Invitrogen	5	4	3	2	64%	36%
mAb clone **PgR 1294**	10	Dako/Agilent	8	1	1	-	90%	80%
mAb clone **PR88**	1	BioGenex	-	-	-	1	-	-
rmAb clone **SP2**	1 1	Diagnostic BioSystems Thermo Scientific	2	-	-	-	-	-
rmAb clone **SP42**	3	Zytomed	-	2	1	-	-	-
rmAb clone **YR85**	1	Fischer Scientific	-	1	-	-	-	-
rmAb clone **ZR4**	1	Zeta Corporation	1	-	-	-	-	-
Ready-To-Use antibodies							Suff.[1]	OR[2]
mAb clone **16** **PA0312 (VRPS[3])**	6	Leica Biosystems	6	-	-	-	100%	100%
mAb clone **16** **PA0312 (LMPS[4])**	12	Leica Biosystems	10	1	1	-	92%	83%
mAb clone **16** **MAD-000670QD**	2	Master Diagnostica	-	-	2	-	-	-
mAb **PgR 636** **IR/IS068 (VRPS[3])**	4	Dako/Agilent	3	1	-	-	-	-
mAb **PgR 636** **IR/IS068 (LMPS[4])**	26	Dako/Agilent	21	3	-	2	92%	81%
mAb **PgR 1294** **GA090 (VRPS[3])**	33	Dako/Agilent	10	22	1	-	97%	30%
mAb **PgR 1294** **GA090 (LMPS[4])**	20	Dako/Agilent	11	5	4	-	80%	55%
rmAb clone **1E2** **790-2223/4296 (VRPS[3])**	53	Ventana/Roche	44	9	-	-	100%	83%
rmAb clone **1E2** **790-2223/4296 (LMPS[4])**	141	Ventana/Roche	108	23	9	1	93%	77%
mAb clone **IHC751** **IHC751**	1	GenomeMe	1	-	-	-	-	-
rmAb clone **SP2** **Kit-0013**	2	Maixin	2	-	-	-	-	-
rmAb clone **Y85** **8360-C010**	4	Sakura Finetek	4	-	-	-	-	-
mAb **PgR 636** **PM343**	1	Biocare Medical	-	1	-	-	-	-
Total	377		258	88	23	8		
Proportion			68%	23%	6%	2%	92%	

1) Proportion of sufficient results (optimal or good) (≥5 asessed protocols).
2) Proportion of optimal results (≥5 asessed protocols).
3) Vendor Recommended Protocol Settings (VRPS) to a specific RTU product applied on the vendor recommended platform(s).
4) Laboratory Modified Protocol Settings (LMPS) to a specific RTU product applied either on the vendor recommended platform(s) or other platforms.

Graph 1. **Pass rate in the NordiQC assessments for PR**



Table 3. **Comparison of pass rates for vendor recommended and laboratory modified RTU protocols**

RTU systems	Vendor recommended protocol settings*		Laboratory modified protocol settings**	
	Sufficient	Optimal	Sufficient	Optimal
Leica BOND MAX/ BOND III mAb 16 **PA0312**	9/9 (100%)	9/9 (100%)	11/11 (100%)	7/11 (64%)
Dako Autotstainer+/ Autostainer Link mAb PgR 636 **IS068/IR068**	8/8 (100%)	6/8 (75%)	17/17 (100%)	15/17 (88%)
Dako Omnis mAb PgR 1294 **GA090**	33/41 (80%)	18/41 (44%)	22/23 (96%)	17/23 (74%)
Ventana BenchMark GX/XT/Ultra rmAb 1E2 **790-2223/790-4296**	62/63 (98%)	38/63 (60%)	128/142 (90%)	87/142 (61%)

* Protocol settings recommended by vendor – Retrieval method and duration, Ab incubation times, detection kit, IHC stainer/equipment
** Modifications included: retrieval method, retrieval duration, retrieval reagents, Ab incubation time and detection kit. Only protocols performed on the specified vendor IHC stainer are included.

Autostainer RTU:
If using Flex+ a pass rate of 100%, 90% optimal.

Omnis RTU:
If using Flex+ a pass rate of 100%, 76% optimal.

HER2 – PITFALLS / POINTS OF ATTENTION

Graph 1. **Pass rates of the HER2 IHC assessments in the NordiQC breast cancer module 2018-2023**



* pass rates using vendor recommended protocol settings

HER2 results, run B35



Do not change to a more sensitive detection system!

PD-L1 IC – PITFALLS/POINTS OF ATTENTION

Table 2. **Assessment marks for IHC assays and antibodies run C13, PD-L1 IC**

CE-IVD / FDA approved PD-L1 assays	n	Vendor	Optimal	Good	Borderline	Poor	Suff.[1]	OR[2]
rmAb clone SP142, **741-4860**[3]	51	Ventana/Roche	24	18	8	1	82%	47%
rmAb clone SP142, **741-4860**[4]	1	Ventana/Roche	0	0	0	1	-	-
rmAb clone SP263, **741-4905**[3]	6	Ventana/Roche	0	3	2	1	50%	0%
rmAb clone SP263, **741-4905**[4]	1	Ventana/Roche	0	0	0	1	-	-
rmAb clone 28-8 pharmDX, **SK005**	1	Dako/Agilent	0	0	0	1	-	-
mAb clone 22C3 pharmDX, **SK006**	2	Dako/Agilent	0	1	1	0	-	-
mAb clone 22C3 pharmDX, **GE006**	3	Dako/Agilent	0	0	0	3	-	-
Antibodies[7] for laboratory developed PD-L1 assays, concentrated antibodies	n	Vendor	Optimal	Good	Borderline	Poor	Suff.[1]	OR[2]
mAb clone **22C3**	4	Dako/Agilent	0	0	0	4	-	-
rmAb clone **ZR3**	1	Zeta Corporation	0	0	0	1	-	-
rmAb clone **CAL10**	4	Zytomed	0	0	4	0	-	-
rmAb clone **E1L3N**	2	Cell Signaling	0	0	2	0	-	-
rmAb clone **QR001**	1	Quartett	0	0	1	0	-	-
rmAb clone **SP142**	1	Abcam	0	1	0	0	-	-
Ready-To-Use antibodies[8]	n	Vendor	Optimal	Good	Borderline	Poor	Suff.[1]	OR[2]
rmAb clone SP142, **790-4860 (VRPS)**[5]	21	Ventana/Roche	13	5	2	1	86%	62%
rmAb clone SP142, **790-4860 (LMPS)**[6]	33	Ventana/Roche	17	9	6	1	79%	52%
rmAb clone SP263, **790-4905**	1	Ventana/Roche	0	1	0	0	-	-
rmAb clone SP263, **790-4905** [4]	2	Ventana/Roche	0	0	2	0	-	-
rmAb clone SP142, **RMA-0724**	2	Fuzhou Maixin	0	2	0	0	-	-
rmAb clone AC37, **PA168**	1	Abcarta	0	0	0	1	-	-
mAb clone C9C9 **CPM-0278**	1	Celnovte	0	0	0	1	-	-
Total	139		54	40	28	17		
Proportion			39%	29%	20%	12%	68%	



PD-L1 IC – ICAPS

rmAb SP142 | mAb 22C3 | rmAb SP142 | mAb 22C3





rmAb SP142 | mAb 22C3 | rmAb SP142 | rmAb ZR3

…YOU SURVIVED! THANK YOU FOR YOUR ATTENTION

BONUS – P120

No NordiQC data available for p120 Catenin.
For the p120 stains below, a concentrated format of the mAb clone MRQ-5 is used.



Ductal breast carcinoma

Lobular breast carcinoma

E-CAD: membranous staining reaction in (most) ductal breast carcinomas, negative in (most) lobular breast carcinomas.

p120: membranous staining reaction in (most) ductal breast carcinomas, cytoplasmic staining reaction in (most) lobular breast carcinomas.

BONUS – P120 ICAPS

No NordiQC data available for p120 Catenin.
For the p120 stains below, a concentrated format of the mAb clone MRQ-5 is used.

Liver:
Hepatocytes must show a weak to moderate membranous staining





Appendix:
Columnar epithelial cells must show a strong membranous staining.